Released Mar 13, 2014, after the close
10-K filed Mar 13, 2014, 72 days after period end · 0001144204-14-015468
Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$10.89M-$10.89M derivedN/M vs Q4 2012N/M vs Q3 2013
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$6,515,000N/M
Operating Incomederived-$17,095,000N/M
Operating Cash Flowderived-$4,742,000N/M
Free Cash Flowderived-$4,964,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2013dderived from reported figures | Q4 2012dderived from reported figures | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $1.17M | $2.36M | — |
| Net Income | -$10.89M | -$9.88M | -$8.91M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR